share_log

Earnings Call Summary | SelectQuote(SLQT.US) Q2 2024 Earnings Conference

moomoo AI ·  Feb 7 13:21  · Conference Call

The following is a summary of the SelectQuote, Inc. (SLQT) Q2 2024 Earnings Call Transcript:

Financial Performance:

  • SelectQuote reported Q2 2024 consolidated revenue of $405 million, growing 27% year-over-year.

  • The Senior segment generated EBITDA margins of 32%.

  • Significant financial growth was seen with a revenue to Customer Acquisition Cost of 4x; over double the rate from 2 years prior.

  • The company achieved breakeven free cash flow for fiscal 2024.

  • The consolidated revenue, adjusted EBITDA outlook for fiscal 2024 was increased.

  • Adjusted EBITDA totaled $67 million compared to $64 million a year ago.

  • The Senior revenue of $248 million grew 11% year-over-year, primarily due to MA policy growth.

Business Progress:

  • The company has continued to optimize its sales force.

  • The company adopted a strategic focus on the highest quality lead sources and carrier partnerships.

  • In the Healthcare Services division, there was a significant growth in prescriptions shipped per day, increasing by 76% year on year.

  • The company added nearly 10,000 members to their Healthcare Services segment.

  • The company plans to enhance SelectRx's overall return, drive higher free cash flow, and increase shareholder value in the future.

  • The company anticipates a growth trend in clients seeking help beyond just Medicare Advantage, aligning their model that targets customers desiring richer benefits.

More details: SelectQuote IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment